• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

德雷维特综合征的临床、经济和人文负担——一项系统的文献综述。

The clinical, economic, and humanistic burden of Dravet syndrome - A systematic literature review.

作者信息

Sullivan Joseph, Deighton Alison M, Vila Maria Candida, Szabo Shelagh M, Maru Benit, Gofshteyn Jacqueline S, James Emma S, Rico Salvador, Zuberi Sameer M

机构信息

University of California, San Francisco, CA, USA.

Broadstreet HEOR, Vancouver, BC, Canada.

出版信息

Epilepsy Behav. 2022 May;130:108661. doi: 10.1016/j.yebeh.2022.108661. Epub 2022 Mar 22.

DOI:10.1016/j.yebeh.2022.108661
PMID:35334258
Abstract

Dravet syndrome (DS) is a developmental and epileptic encephalopathy with evolving disease course as individuals age. In recent years, the treatment landscape of DS has changed considerably, and a comprehensive systematic review of the contemporary literature is lacking. Here we synthesized published evidence on the occurrence of clinical impacts by age, the economic and humanistic (health-related quality-of-life [HRQoL]) burden, and health state utility. We provide an evidence-based, contemporary visualization of the clinical manifestations, highlighting that DS is not limited to seizures; non-seizure manifestations appear early in life and increase over time, contributing significantly to the economic and humanistic burden of disease. The primary drivers of HRQoL in DS include seizure severity, cognition, and motor and behavioral problems; in turn, these directly affect caregivers through the extent of assistance required and consequent impact on activities of daily living. Unsurprisingly, costs are driven by seizure-related events, hospitalizations, and in-home medical care visits. This systematic review highlights a paucity of longitudinal data; most studies meeting inclusion criteria were cross-sectional or had short follow-up. Nonetheless, available data illustrate the substantial impact on individuals, their families, and healthcare systems and establish the need for novel therapies to address the complex spectrum of DS manifestations.

摘要

德拉韦综合征(DS)是一种随着个体年龄增长而病情不断演变的发育性癫痫性脑病。近年来,DS的治疗格局发生了很大变化,但缺乏对当代文献的全面系统综述。在此,我们综合了已发表的关于不同年龄段临床影响的发生情况、经济和人文(与健康相关的生活质量[HRQoL])负担以及健康状态效用的证据。我们提供了基于证据的当代临床表现可视化展示,强调DS不仅限于癫痫发作;非癫痫发作表现出现在生命早期且随时间增加,对疾病的经济和人文负担有显著影响。DS中HRQoL的主要驱动因素包括癫痫发作严重程度、认知以及运动和行为问题;反过来,这些因素通过所需的协助程度以及对日常生活活动的后续影响直接影响照料者。不出所料,成本由与癫痫发作相关的事件、住院和家庭医疗就诊驱动。这项系统综述突出了纵向数据的匮乏;大多数符合纳入标准的研究是横断面研究或随访时间较短。尽管如此,现有数据说明了对个体、其家庭和医疗保健系统的重大影响,并确立了开发新疗法以应对DS复杂表现谱的必要性。

相似文献

1
The clinical, economic, and humanistic burden of Dravet syndrome - A systematic literature review.德雷维特综合征的临床、经济和人文负担——一项系统的文献综述。
Epilepsy Behav. 2022 May;130:108661. doi: 10.1016/j.yebeh.2022.108661. Epub 2022 Mar 22.
2
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
3
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.芬氟拉明治疗德拉韦综合征:NICE 单一技术评估的证据审查组观点。
Pharmacoeconomics. 2023 Jan;41(1):33-42. doi: 10.1007/s40273-022-01209-8. Epub 2022 Oct 27.
4
Dravet syndrome: Effects on informal caregivers' mental health and quality of life - A systematic review.德拉韦特综合征:对非正规照护者心理健康和生活质量的影响——系统评价。
Epilepsy Behav. 2021 Sep;122:108206. doi: 10.1016/j.yebeh.2021.108206. Epub 2021 Jul 16.
5
Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review.拉莫三嗪与卡马西平单药治疗癫痫的疗效比较:个体参与者数据回顾
Cochrane Database Syst Rev. 2018 Jun 28;6(6):CD001031. doi: 10.1002/14651858.CD001031.pub4.
6
A systematic review of adults with Dravet syndrome.Dravet 综合征成人患者的系统性综述。
Seizure. 2021 Apr;87:39-45. doi: 10.1016/j.seizure.2021.02.025. Epub 2021 Feb 22.
7
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
8
How lived experiences of illness trajectories, burdens of treatment, and social inequalities shape service user and caregiver participation in health and social care: a theory-informed qualitative evidence synthesis.疾病轨迹的生活经历、治疗负担和社会不平等如何影响服务使用者和照顾者参与健康和社会护理:一项基于理论的定性证据综合分析
Health Soc Care Deliv Res. 2025 Jun;13(24):1-120. doi: 10.3310/HGTQ8159.
9
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
10
Treatments for seizures in catamenial (menstrual-related) epilepsy.月经性(与月经相关)癫痫发作的治疗。
Cochrane Database Syst Rev. 2021 Sep 16;9(9):CD013225. doi: 10.1002/14651858.CD013225.pub3.

引用本文的文献

1
Nonseizure Outcomes in Dravet Syndrome: Potential Impact of Pharmacotherapy.德雷维特综合征的非癫痫发作结局:药物治疗的潜在影响。
CNS Drugs. 2025 Aug 21. doi: 10.1007/s40263-025-01212-5.
2
Retrospective Multicenter Chart Review Study of Adjunctive Cannabidiol for Seizures Associated with Lennox-Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex.辅助性大麻二酚治疗与伦诺克斯-加斯托综合征、德雷维特综合征和结节性硬化症相关癫痫发作的回顾性多中心病历审查研究
Neurol Ther. 2025 Jul 12. doi: 10.1007/s40120-025-00788-w.
3
Assessing the impact of Dravet syndrome on caregivers' quality of life and perceived burden in Poland.
评估在波兰,德雷维特综合征对照料者生活质量和感知负担的影响。
BMC Psychol. 2025 Jul 9;13(1):763. doi: 10.1186/s40359-025-03102-3.
4
Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome.芬氟拉明在患有德雷维特综合征的儿童和成人中的长期安全性和有效性。
Epilepsia. 2025 Jun;66(6):1919-1932. doi: 10.1111/epi.18342. Epub 2025 Mar 12.
5
Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis.大麻二酚作为伦诺克斯-加斯托综合征辅助治疗的价值:成本效益和预算影响分析。
BMC Med. 2025 Mar 5;23(1):135. doi: 10.1186/s12916-025-03972-9.
6
Development and refinement of the Clinical Global Impression of Improvement for Non-seizure Symptoms measure in Dravet syndrome and Lennox-Gastaut syndrome.用于Dravet综合征和Lennox-Gastaut综合征非癫痫症状的临床整体改善印象量表的开发与完善
J Patient Rep Outcomes. 2025 Feb 21;9(1):24. doi: 10.1186/s41687-024-00829-2.
7
Communicating a diagnosis of Dravet syndrome to parents/caregivers: An international Delphi consensus.向父母/照顾者传达德拉韦特综合征的诊断:一项国际德尔菲共识。
Epilepsia Open. 2025 Apr;10(2):450-465. doi: 10.1002/epi4.13127. Epub 2025 Feb 1.
8
Cause of Death Analysis in a 9½-Year-Old with COVID-19 and Dravet Syndrome.一名9岁半的新冠病毒病(COVID-19)合并德雷维特综合征患儿的死因分析
Pathophysiology. 2025 Jan 10;32(1):3. doi: 10.3390/pathophysiology32010003.
9
Cost-Utility Analysis of Add-on Cannabidiol vs Usual Care Alone for the Treatment of Seizures in Patients With Treatment-Resistant Lennox-Gastaut Syndrome or Dravet Syndrome in the Netherlands.荷兰针对难治性伦诺克斯-加斯托综合征或德雷维特综合征患者,辅助使用大麻二酚与单纯常规治疗相比的成本效用分析。
J Health Econ Outcomes Res. 2024 Dec 23;11(2):168-179. doi: 10.36469/001c.126071. eCollection 2024.
10
Understanding the Burden of Lennox-Gastaut Syndrome: Implications for Patients, Caregivers, and Society in High and Low Resource Settings: A Narrative Review.了解伦诺克斯-加斯东综合征的负担:对高资源和低资源环境下患者、护理人员及社会的影响:一项叙述性综述
Health Sci Rep. 2024 Dec 12;7(12):e70169. doi: 10.1002/hsr2.70169. eCollection 2024 Dec.